Shenzhen Ausa Pharmaceutical

Shenzhen Ausa Pharmaceutical is a leading Chinese biopharmaceutical company focused on the precision treatment of cardiovascular and cerebrovascular diseases. The company is widely recognized for developing Huanshu (Enalapril Maleate + Folic Acid Tablets), the first innovative drug globally designed specifically to treat H-type hypertension and reduce stroke risk. Ausa integrates genomic research with clinical medicine, utilizing companion diagnostics to identify patient genotypes that respond best to specific therapies. Their operations span the entire value chain, including basic research, clinical trials, GMP manufacturing, and large-scale commercialization. The company's approach emphasizes the prevention of chronic diseases through personalized medicine and large-scale epidemiological data.